This site is intended for healthcare professionals

Close up of arthritic hands holding a green apple

Arthritis

Containing dedicated Learning Zones, guidelines, trials, journals and news

Last updated: 3rd Sep 2024

Arthritis refers to a collection of diseases that affect the joints, causing pain and stiffness. There are more than one hundred types of arthritis which can be broadly categorised as either inflammatory or non-inflammatory.

Non-inflammatory arthritis includes osteoarthritis, the most common form of arthritis. Osteoarthritis involves degeneration of the articular cartilage that protects the ends of the bones and is a leading cause of disability around the world.

Inflammatory arthritis may arise as the result of an autoimmune or autoinflammatory response. Examples include rheumatoid arthritis and spondyloarthropathies such as ankylosing spondylitis and psoriatic arthritis.

There is no known cure for arthritis, so current treatment strategies focus on providing effective palliation and slowing disease progression. Treatment may vary considerably depending upon type and severity.

Close up of arthritic hands holding a green apple

Independent, grant-supported education for arthritis

In this section

Cut-through image of a knee joint showing severe arthritis highlighted in red

Osteoarthritis

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

Blue test tubes arranged in a line, disappearing into the background

Kevzara (sarilumab) approved by FDA for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA)

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Kevzara (sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA), a form of arthritis that impacts multiple joints at a time

1 mins

CHMP positive recommendation for Tofidence (tocilizumab biosimilar)

Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Tofidence (tocilizumab), a biosimilar monoclonal antibody referencing Rocactemra

1 min

Metoject subcutaneous injection pen (methotrexate) pen -type autoinjector approved in Japan

Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector “Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL” (methotrexate)

1 min

See all news

Related Journal Articles

Neurobiology of osteoarthritis: a systematic review and activation likelihood estimation meta-analysis

1 mins

To what extent is severe osteoarthritis preventable? Occupational and non-occupational risk factors for knee and hip osteoarthritis

1 mins

Whole grain consumption and risk of radiographic knee osteoarthritis: a prospective study from the Osteoarthritis Initiative

1 mins

Association of physical activity with physical function and quality of life in people with hip and knee osteoarthritis: longitudinal analysis of a population-based cohort

1 mins

Bone in osteoarthritis: imaging and interventions

1 mins

Ribosome dysfunction in osteoarthritis

1 mins

Erosive hand osteoarthritis: latest findings and outlook

1 mins

Obesity, Inflammation, and Immune System in Osteoarthritis

1 mins

Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis

1 mins

Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis

1 mins

Osteoarthritis year in review 2022: Genetics, genomics and epigenetics

1 mins

How does hip osteoarthritis differ from knee osteoarthritis?

1 mins

The Role of Genetics and Epigenetic Regulation in the Pathogenesis of Osteoarthritis

1 mins

Lubricants for osteoarthritis treatment: From natural to bioinspired and alternative strategies

1 mins

The Role of Ferroptosis in the Pathogenesis of Osteoarthritis

1 mins

Osteoarthritis: a narrative review of molecular approaches to disease management

1 mins

Inflammation in osteoarthritis: the latest progress and ongoing challenges

1 mins

Osteoarthritis year in review 2022: imaging

1 mins

Osteoarthritis gene therapy in 2022

1 mins

Inflammaging and Osteoarthritis

1 mins

Osteoarthritis year in review 2022: rehabilitation

1 mins

Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink

1 mins

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

2 mins

Upadacitinib for the treatment of rheumatoid arthritis.

1 mins

Integrating biosimilars into clinical practice

1 mins

Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.

1 mins

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

1 mins

Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.

1 mins

Bimekizumab for the treatment of psoriatic disease

1 mins

Anti-il-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review

1 mins

Related Guidelines

Guidelines

EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis

These evidence-based recommendations and related research agenda provide the basis for sensible use of imaging in routine clinical assessment of people with OA.

1 mins

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.

1 min

BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs

The purpose of this guideline is to provide up-to-date, evidence-based recommendations for the safe use of non-biologic DMARDs in adults (>16 years old).

1 min

See all guidelines

Related Clinical Trials

A close up image of a microscope

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY)

4 mins

A close up image of a microscope

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)

1 mins

A close up image of a microscope

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)

4 mins

A close up image of a microscope

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

3 mins

A close up image of a microscope

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

3 mins

A close up image of a microscope

Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics

2 mins

A close up image of a microscope

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

4 mins

A close up image of a microscope

A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis

1 mins

A close up image of a microscope

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND

4 mins

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event